膀胱癌市场:KOL的洞察

本报告提供全球膀胱癌市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

治疗流程

调查目的

免疫疗法

• 已上市治疗方法
  • Keytruda（pembrolizumab，默克公司）
  • Opdivo（纳武单抗，百时美施贵宝）
  • Tecentriq（atezolizumab，罗氏）
  • Bavencio（Avelumab，默克集团/辉瑞）
• 管道疗法
  • Imfinzi（durvalumab、阿斯特捷利康）
  • Sasanlimab（辉瑞）
  • Cetrelimab（杨森）

抗体-药物结合物

• 市售治疗方法
  • Padocev（enfortumab vedotin，Astellas/Seagen）(9)
  • Trodelvy（sacituzumab govitecan，吉利德）(12)

纤维母细胞生长因子受体 (FGFR) 抑制剂

• 市售治疗方法
  • Balversa（erdafitinib、杨森）

酪胺酸激?抑制剂

• 管道疗法
  • Cabometyx（卡博替尼、Exelixis/Ipsen）

其他作用机转

• 市售治疗方法
  • Adostiladrine（nadofaragenfiladenovec，FKD Therapies/Ferring Pharmaceuticals）
• 管道疗法
  • Anctiva（N-803，ImmunityBio）
  • CG0070（cletostimogen grenadenorepvec，CG 肿瘤学）
  • Ruvidal（TLD-1433，Theralase）

未来的治疗范例

• 主要见解摘要 (7)
  • 用于更好地选择患者的生物标记仍然是膀胱癌中未满足的重要需求

附录

KOL突发新闻

While Merck & Co Keytruda + Astellas/Seagen's Padcev forges ahead, how do KOLs see the prospects of Keytruda + Taiho Pharmaceutical's futibatinib combination? How do experts assess FKD Therapies/Ferring Pharmaceuticals much needed Adstiladrin? Could a combination therapy strategy reinvigorate AstraZeneca's Imfinzi? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.

• 03 Oct 23 KOL Bulletin -- Views on the results of Phase III EV-302 trial of Keytruda and Padcev in bladder cancer

Table of Contents

Executive summary (3)

Treatment algorithm

Research objectives (5)

Immunotherapies (69)

• Marketed therapies (42)
  • Keytruda (pembrolizumab; Merck & Co.) (13)
  • Opdivo (nivolumab; Bristol Myers Squibb) (14)
  • Tecentriq (atezolizumab; Roche) (6)
  • Bavencio (avelumab; Merck Group/Pfizer) (9)
• Pipeline therapies (27)
  • Imfinzi (durvalumab; AstraZeneca) (11)
  • Sasanlimab (Pfizer) (8)
  • Cetrelimab (Janssen) (8)

Antibody-drug conjugates (21)

• Marketed therapies (21)
  • Padcev (enfortumab vedotin; Astellas/Seagen) (9)
  • Trodelvy (sacituzumab govitecan; Gilead) (12)

Fibroblast growth factor receptor (FGFR) inhibitors (9)

• Marketed therapies (9)
  • Balversa (erdafitinib; Janssen) (9)

Tyrosine kinase inhibitors (7)

• Pipeline therapies (7)
  • Cabometyx (cabozantinib; Exelixis/Ipsen) (7)

Other modes of action (34)

• Marketed therapies (11)
  • Adstiladrin (nadofaragene firadenovec; FKD Therapies/Ferring Pharmaceuticals) (11)
• Pipeline therapies (23)
  • Anktiva (N-803; ImmunityBio) (10)
  • CG0070 (cretostimogene grenadenorepvec; CG Oncology) (6)
  • Ruvidar (TLD-1433; Theralase) (7)

Future treatment paradigm (7)

• Key insights summary (7)
  • Biomarkers for better patient selection remain an important unmet need in bladder cancer (5)

Appendix (3)

• KOL details (3)
  • KOLs from North America (1)
  • KOLs from Europe (1)

KOL Bulletins (2)